Penmenvy combines the antigenic components of Bexsero (meningococcal Group B vaccine) and Menveo (meningococcal Groups A, C, Y, and W-135 oligosaccharide diphtheria CRM197 conjugate vaccine).

For patients transitioning from rituximab to ravulizumab, meningococcal vaccination can be safely done within 6 months after stopping rituximab.

The latest meeting of the US CDC Advisory Committee on Immunization Practices has been postponed indefinitely to allow time for public comments to be collected.

March 4 is International Human Papillomavirus (HPV) Awareness Day. The New York State Department of Health is stressing the ...

HHS Secretary Robert F. Kennedy Jr. appears to be planning major changes to the way his department oversees vaccines, media ...